Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01305538 | Crossover Post-herpetic Neuralgia (PHN) | PHASE2 | COMPLETED | 100 | — | — | Mar 1, 2011 | Jun 1, 2012 | Dec 7, 2015 | 23 | United States, France |
| Arm | Type | Description |
|---|---|---|
| Arm 1 BMS-954561 40mg or 80mg | OTHER | Arm description: BMS-954561 40mg or 80mg three times daily (TID) to Placebo OR Placebo to 40mg or 80mg TID. Arm type: Active to Placebo or Placebo to Active (cross-over) |
| Arm 2 BMS-954561 150mg or 300mg | OTHER | Arm description: BMS-954561 150mg or 300mg TID to Placebo OR Placebo to 150mg or 300mg TID Arm type: Active to Placebo or Placebo to Active(cross-over) |
| Name | Type | Description |
|---|---|---|
| BMS-954561 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Patient with Post-Herpetic Neuralgia (PHN) as defined as pain present for more than 6 months after the onset of a herpes zoster skin rash affecting the trigeminal, cervical, thoracic, lumbar, or sacral regions. * Based on patient diary information collected during the Baseline...